Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6219753 | 0.86 | FNTA (0.53) | ALDH1A1LMNACYP1A2CYP2D6MAPT | |
| SCHEMBL6806320 | 0.85 | MAPT (0.45) | LMNACYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL6219371 | 0.83 | KMT2A (0.47) | ALDH1A1LMNAMAPTL3MBTL1CES2 | |
| SCHEMBL6219618 | 0.83 | MAPK1 (0.48) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6219202 | 0.80 | KMT2A (0.42) | ALDH1A1LMNACYP1A2CYP2D6MAPT | |
| SCHEMBL6220407 | 0.79 | MAPK1 (0.51) | ALDH1A1LMNAMAPTL3MBTL1SRD5A2 | |
| SCHEMBL28115157 | 0.79 | FNTA (0.44) | ALDH1A1LMNAMAPTL3MBTL1AKR1C3 | |
| SCHEMBL6220270 | 0.77 | SRD5A2 (0.45) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL28115613 | 0.76 | FNTA (0.59) | ALDH1A1LMNACYP1A2CYP2D6MAPT | |
| SCHEMBL6799716 | 0.75 | PBRM1 (0.56) | ALDH1A1LMNACYP1A2CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537105-A2 | SYNTHESIS OF INDOLIZINES | Synta Pharmaceuticals Corporation (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040152897-A1 | Synthesis of indolizines | SYNTA PHARMACEUTICALS CORP. (US) | 2004-08-05 | — | — | US | disclosed |
| WO-2004024727-A2 | SYNTHESIS OF INDOLIZINES | SYNTA PHARMACEUTICALS CORP. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152897-A1 | Synthesis of indolizines | INMT, IDO1, IDO2 | ALDH1A1 1637/4885LMNA 2205/4885CYP1A2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.